Conceptualizing Overdiagnosis in Cancer Screening

The aim of cancer screening is to detect asymptomatic cancers whose treatment will result in extension of life, relative to length of life absent screening. Unfortunately, cancer screening also results in overdiagnosis, the detection of cancers that, in the absence of screening, would not present sy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 2015-04, Vol.107 (4), p.1
Hauptverfasser: Marcus, Pamela M, Prorok, Philip C, Miller, Anthony B, DeVoto, Emily J, Kramer, Barnett S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page 1
container_title JNCI : Journal of the National Cancer Institute
container_volume 107
creator Marcus, Pamela M
Prorok, Philip C
Miller, Anthony B
DeVoto, Emily J
Kramer, Barnett S
description The aim of cancer screening is to detect asymptomatic cancers whose treatment will result in extension of life, relative to length of life absent screening. Unfortunately, cancer screening also results in overdiagnosis, the detection of cancers that, in the absence of screening, would not present symptomatically during one's lifetime. Thus, their detection and subsequent treatment is unnecessary and detrimental. This definition of overdiagnosis, while succinct, does not capture the ways it can occur, and our interactions with patients, advocates, researchers, clinicians, and journalists have led us to believe that the concept of overdiagnosis is difficult to explain and, for some, difficult to accept. We propose a dichotomy, the "tumor-patient" classification, to aid in understanding overdiagnosis. The tumor category includes asymptomatic malignant disease that would regress spontaneously if left alone, as well as asymptomatic malignant disease that stagnates or progresses too slowly to be life threatening in even the longest of lifetimes. The patient category includes asymptomatic malignant disease that would progress quickly enough to be life threatening during a lifetime of typical length, but lacks clinical relevance because death due to another cause intercedes prior to what would have been the date of symptomatic diagnosis had screening not occurred. Cancer screening of most organs is likely to result in overdiagnosis of both types. However, the ratio of tumor- to patient-driven overdiagnosis almost certainly varies, and may vary drastically, by organ, screening modality, patient characteristics, and other factors.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1675779334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3665885961</sourcerecordid><originalsourceid>FETCH-proquest_journals_16757793343</originalsourceid><addsrcrecordid>eNpjYuA0NDEz0DUyNDBlYeA0MDAy17WwMDfhYOAqLs4yAAJLIxNOBkPn_Lzk1IKS0sSczKrMvHQF_7LUopTMxPS8_OLMYoXMPAXnRKCCIoXg5KLU1DygCh4G1rTEnOJUXijNzaDs5hri7KFbUJRfWJpaXBKflV9alAeUijc0Mzc1N7c0NjYxJk4VAK9WNSE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1675779334</pqid></control><display><type>article</type><title>Conceptualizing Overdiagnosis in Cancer Screening</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Marcus, Pamela M ; Prorok, Philip C ; Miller, Anthony B ; DeVoto, Emily J ; Kramer, Barnett S</creator><creatorcontrib>Marcus, Pamela M ; Prorok, Philip C ; Miller, Anthony B ; DeVoto, Emily J ; Kramer, Barnett S</creatorcontrib><description>The aim of cancer screening is to detect asymptomatic cancers whose treatment will result in extension of life, relative to length of life absent screening. Unfortunately, cancer screening also results in overdiagnosis, the detection of cancers that, in the absence of screening, would not present symptomatically during one's lifetime. Thus, their detection and subsequent treatment is unnecessary and detrimental. This definition of overdiagnosis, while succinct, does not capture the ways it can occur, and our interactions with patients, advocates, researchers, clinicians, and journalists have led us to believe that the concept of overdiagnosis is difficult to explain and, for some, difficult to accept. We propose a dichotomy, the "tumor-patient" classification, to aid in understanding overdiagnosis. The tumor category includes asymptomatic malignant disease that would regress spontaneously if left alone, as well as asymptomatic malignant disease that stagnates or progresses too slowly to be life threatening in even the longest of lifetimes. The patient category includes asymptomatic malignant disease that would progress quickly enough to be life threatening during a lifetime of typical length, but lacks clinical relevance because death due to another cause intercedes prior to what would have been the date of symptomatic diagnosis had screening not occurred. Cancer screening of most organs is likely to result in overdiagnosis of both types. However, the ratio of tumor- to patient-driven overdiagnosis almost certainly varies, and may vary drastically, by organ, screening modality, patient characteristics, and other factors.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>CODEN: JNCIEQ</identifier><language>eng</language><publisher>Oxford: Oxford Publishing Limited (England)</publisher><subject>Asymptotic methods ; Cancer ; Medical diagnosis ; Medical screening ; Oncology ; Tumors</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2015-04, Vol.107 (4), p.1</ispartof><rights>Copyright Oxford Publishing Limited(England) Apr 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Marcus, Pamela M</creatorcontrib><creatorcontrib>Prorok, Philip C</creatorcontrib><creatorcontrib>Miller, Anthony B</creatorcontrib><creatorcontrib>DeVoto, Emily J</creatorcontrib><creatorcontrib>Kramer, Barnett S</creatorcontrib><title>Conceptualizing Overdiagnosis in Cancer Screening</title><title>JNCI : Journal of the National Cancer Institute</title><description>The aim of cancer screening is to detect asymptomatic cancers whose treatment will result in extension of life, relative to length of life absent screening. Unfortunately, cancer screening also results in overdiagnosis, the detection of cancers that, in the absence of screening, would not present symptomatically during one's lifetime. Thus, their detection and subsequent treatment is unnecessary and detrimental. This definition of overdiagnosis, while succinct, does not capture the ways it can occur, and our interactions with patients, advocates, researchers, clinicians, and journalists have led us to believe that the concept of overdiagnosis is difficult to explain and, for some, difficult to accept. We propose a dichotomy, the "tumor-patient" classification, to aid in understanding overdiagnosis. The tumor category includes asymptomatic malignant disease that would regress spontaneously if left alone, as well as asymptomatic malignant disease that stagnates or progresses too slowly to be life threatening in even the longest of lifetimes. The patient category includes asymptomatic malignant disease that would progress quickly enough to be life threatening during a lifetime of typical length, but lacks clinical relevance because death due to another cause intercedes prior to what would have been the date of symptomatic diagnosis had screening not occurred. Cancer screening of most organs is likely to result in overdiagnosis of both types. However, the ratio of tumor- to patient-driven overdiagnosis almost certainly varies, and may vary drastically, by organ, screening modality, patient characteristics, and other factors.</description><subject>Asymptotic methods</subject><subject>Cancer</subject><subject>Medical diagnosis</subject><subject>Medical screening</subject><subject>Oncology</subject><subject>Tumors</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpjYuA0NDEz0DUyNDBlYeA0MDAy17WwMDfhYOAqLs4yAAJLIxNOBkPn_Lzk1IKS0sSczKrMvHQF_7LUopTMxPS8_OLMYoXMPAXnRKCCIoXg5KLU1DygCh4G1rTEnOJUXijNzaDs5hri7KFbUJRfWJpaXBKflV9alAeUijc0Mzc1N7c0NjYxJk4VAK9WNSE</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Marcus, Pamela M</creator><creator>Prorok, Philip C</creator><creator>Miller, Anthony B</creator><creator>DeVoto, Emily J</creator><creator>Kramer, Barnett S</creator><general>Oxford Publishing Limited (England)</general><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20150401</creationdate><title>Conceptualizing Overdiagnosis in Cancer Screening</title><author>Marcus, Pamela M ; Prorok, Philip C ; Miller, Anthony B ; DeVoto, Emily J ; Kramer, Barnett S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_16757793343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Asymptotic methods</topic><topic>Cancer</topic><topic>Medical diagnosis</topic><topic>Medical screening</topic><topic>Oncology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marcus, Pamela M</creatorcontrib><creatorcontrib>Prorok, Philip C</creatorcontrib><creatorcontrib>Miller, Anthony B</creatorcontrib><creatorcontrib>DeVoto, Emily J</creatorcontrib><creatorcontrib>Kramer, Barnett S</creatorcontrib><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marcus, Pamela M</au><au>Prorok, Philip C</au><au>Miller, Anthony B</au><au>DeVoto, Emily J</au><au>Kramer, Barnett S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conceptualizing Overdiagnosis in Cancer Screening</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><date>2015-04-01</date><risdate>2015</risdate><volume>107</volume><issue>4</issue><spage>1</spage><pages>1-</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><coden>JNCIEQ</coden><abstract>The aim of cancer screening is to detect asymptomatic cancers whose treatment will result in extension of life, relative to length of life absent screening. Unfortunately, cancer screening also results in overdiagnosis, the detection of cancers that, in the absence of screening, would not present symptomatically during one's lifetime. Thus, their detection and subsequent treatment is unnecessary and detrimental. This definition of overdiagnosis, while succinct, does not capture the ways it can occur, and our interactions with patients, advocates, researchers, clinicians, and journalists have led us to believe that the concept of overdiagnosis is difficult to explain and, for some, difficult to accept. We propose a dichotomy, the "tumor-patient" classification, to aid in understanding overdiagnosis. The tumor category includes asymptomatic malignant disease that would regress spontaneously if left alone, as well as asymptomatic malignant disease that stagnates or progresses too slowly to be life threatening in even the longest of lifetimes. The patient category includes asymptomatic malignant disease that would progress quickly enough to be life threatening during a lifetime of typical length, but lacks clinical relevance because death due to another cause intercedes prior to what would have been the date of symptomatic diagnosis had screening not occurred. Cancer screening of most organs is likely to result in overdiagnosis of both types. However, the ratio of tumor- to patient-driven overdiagnosis almost certainly varies, and may vary drastically, by organ, screening modality, patient characteristics, and other factors.</abstract><cop>Oxford</cop><pub>Oxford Publishing Limited (England)</pub></addata></record>
fulltext fulltext
identifier ISSN: 0027-8874
ispartof JNCI : Journal of the National Cancer Institute, 2015-04, Vol.107 (4), p.1
issn 0027-8874
1460-2105
language eng
recordid cdi_proquest_journals_1675779334
source Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Asymptotic methods
Cancer
Medical diagnosis
Medical screening
Oncology
Tumors
title Conceptualizing Overdiagnosis in Cancer Screening
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A51%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conceptualizing%20Overdiagnosis%20in%20Cancer%20Screening&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Marcus,%20Pamela%20M&rft.date=2015-04-01&rft.volume=107&rft.issue=4&rft.spage=1&rft.pages=1-&rft.issn=0027-8874&rft.eissn=1460-2105&rft.coden=JNCIEQ&rft_id=info:doi/&rft_dat=%3Cproquest%3E3665885961%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1675779334&rft_id=info:pmid/&rfr_iscdi=true